Northern Capital Management LLC trimmed its position in shares of PerkinElmer, Inc. (NYSE:PKI) by 12.9% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 16,995 shares of the medical research company’s stock after selling 2,515 shares during the period. Northern Capital Management LLC’s holdings in PerkinElmer were worth $1,653,000 at the end of the most recent reporting period.
Several other hedge funds have also recently made changes to their positions in the company. Select Equity Group L.P. grew its stake in PerkinElmer by 7.2% during the second quarter. Select Equity Group L.P. now owns 8,626,977 shares of the medical research company’s stock valued at $631,754,000 after acquiring an additional 578,940 shares in the last quarter. Janus Henderson Group PLC grew its stake in PerkinElmer by 0.4% during the second quarter. Janus Henderson Group PLC now owns 6,359,094 shares of the medical research company’s stock valued at $465,676,000 after acquiring an additional 22,710 shares in the last quarter. Massachusetts Financial Services Co. MA grew its stake in PerkinElmer by 4.4% during the third quarter. Massachusetts Financial Services Co. MA now owns 3,413,223 shares of the medical research company’s stock valued at $332,004,000 after acquiring an additional 144,602 shares in the last quarter. Partner Fund Management L.P. grew its stake in PerkinElmer by 7.4% during the second quarter. Partner Fund Management L.P. now owns 1,161,817 shares of the medical research company’s stock valued at $85,080,000 after acquiring an additional 80,310 shares in the last quarter. Finally, Schroder Investment Management Group grew its stake in PerkinElmer by 6.3% during the second quarter. Schroder Investment Management Group now owns 777,808 shares of the medical research company’s stock valued at $56,305,000 after acquiring an additional 46,316 shares in the last quarter. Hedge funds and other institutional investors own 95.69% of the company’s stock.
In other PerkinElmer news, Director Nicholas A. Lopardo sold 2,700 shares of PerkinElmer stock in a transaction on Friday, August 31st. The shares were sold at an average price of $92.28, for a total value of $249,156.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Patrick J. Sullivan sold 10,000 shares of PerkinElmer stock in a transaction on Tuesday, November 13th. The stock was sold at an average price of $81.64, for a total transaction of $816,400.00. The disclosure for this sale can be found here. Insiders sold a total of 28,949 shares of company stock valued at $2,575,140 over the last three months. Corporate insiders own 2.10% of the company’s stock.
PKI opened at $82.29 on Friday. PerkinElmer, Inc. has a fifty-two week low of $69.21 and a fifty-two week high of $98.33. The firm has a market cap of $8.85 billion, a P/E ratio of 23.34, a P/E/G ratio of 1.78 and a beta of 1.11. The company has a debt-to-equity ratio of 0.73, a current ratio of 1.70 and a quick ratio of 1.18.
PerkinElmer (NYSE:PKI) last issued its quarterly earnings data on Wednesday, October 31st. The medical research company reported $0.90 EPS for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.02). PerkinElmer had a return on equity of 15.04% and a net margin of 4.71%. The business had revenue of $674.30 million during the quarter, compared to analysts’ expectations of $676.72 million. During the same period in the previous year, the business earned $0.73 earnings per share. The business’s quarterly revenue was up 21.7% on a year-over-year basis. As a group, research analysts predict that PerkinElmer, Inc. will post 3.6 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, February 8th. Shareholders of record on Friday, January 18th will be paid a $0.07 dividend. The ex-dividend date is Thursday, January 17th. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.34%. PerkinElmer’s payout ratio is currently 9.66%.
COPYRIGHT VIOLATION WARNING: This piece was reported by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright & trademark laws. The legal version of this piece can be read at https://sportsperspectives.com/2018/11/17/perkinelmer-inc-pki-stake-lowered-by-northern-capital-management-llc.html.
PerkinElmer, Inc provides products, services, and solutions to the diagnostics, research, environmental, industrial, food, and laboratory services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers analytical technologies, solutions, and services for the environmental market that enable its customers to understand the characterization and health of various aspects, including air, water, and soil.
Featured Article: Investing in Growth Stocks
Want to see what other hedge funds are holding PKI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PerkinElmer, Inc. (NYSE:PKI).
Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.